Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer

Anticancer Research

Volumn 24, Issue 4, 2004, Pages 2465-2470

  Koizumi, Wasaburo ^a   Fukuyama, Yoshio ^b   Fukuda, Takahiro ^c   Akiya, Toshikazu ^c   Hasegawa, Kouichi ^d   Kojima, Yasuaki ^e   Ohno, Nobutsugu ^f   Kurihara, Minoru ^g  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KIMITSU CHUO HOSPITAL   (Japan)

^c GUNMA CANCER CENTER HOSPITAL   (Japan)

^d Tsuboi Hospital   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^g SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Combination therapy; Doxifluridine; Gastric cancer; Inoperable; Mitomycin

Indexed keywords

CAPECITABINE; CISPLATIN; DOXIFLURIDINE; FLUOROPYRIMIDINE; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH CANCER; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; STOMACH NEOPLASMS;

EID: 4444251693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cancer statistics in Japan Editorial board. Cancer statistics in Japan 1999, Kakizoe T (ed), Foundation for Promotion of Cancer Research, Tokyo, 1999; pp. 54.
2. Sakata Y, Ohtsu A, Horikoshi N et al: Late phase II study of oral fluoropyrimidine anti-cancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998.
3. Sakata Y, Nakao I, Futatsuki K et al: An early phase II trial of CPT-11 in patients with advanced gastrointestinal cancer. J Jpn Soc Cancer Ther 27: 2028-2035, 1992.
4. Taguchi T, Sakata Y, Kanamaru R et al: A late phase II study of RP56976 (Docetaxel) in patients with advanced/recurrent gastric cancer. Jpn J Cancer Chemother 25: 1915-1923, 1998.
5. Saikawa Y, Kubota T, Kuo T et al: Synergistic antitumor activity of mitomycin C and cisplatin against gastric cancer cells in vitro. J Surg Oncol 54: 98-102, 1993.
6. Fujita F, Fujita M, Shimozuma K et al: Combination chemotherapy of human gastrointestinal and breast cancer xenografts in nude mice with 5′-deoxy-5-fluorouridine and mitomycin C. J Jpn Soc Cancer Ther 21: 1386-1396, 1986.
7. Kurihara M, Izumi T, Yoshida S et al: A cooperative randomized study on tegafur plus mitimycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. J Jpn Cancer Res 82: 613-620, 1991.
8. Koizumi W, Kurihara M, Hasegawa K et al: Combination therapy with cisplatin, 5′-deoxy-5-fluorouridine (5′-DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastric cancer: a randomized trial comparing two dosage regimens. Oncol Rep 3: 255-260, 1996.
9. Koizumi W, Kurihara M, Sasai T et al: A phase II study of combination therapy with 5′-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci. Cancer 72: 658-662, 1993.
10. Niitani H, Kimura K, Saito T et al: Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer-multi-institutional cooperative study-. Jpn J Cancer Chemother 12: 2044-2051, 1985.
11. Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English edition. Nishi M, Omori Y and Miwa K (eds), Kanehara and Co., Ltd., Tokyo, 1995; pp. 89-100.
12. Pratesi G, Gianni L, Manzotti C et al: Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination on primary colon tumors in mice. Cancer Chemother Pharmacol 21: 237-240, 1988.
13. Scanlon KJ, Newman EM, Lu Y et al: Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83: 8923-8925, 1986.
14. Koizumi W, Kurihara M, Nakano S et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 50: 191-197, 2000.
15. Koizumi W, Tanabe S, Saigenji K et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
16. Koizumi W, Saigenji K, Ujiie S et al: A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 64: 232-236, 2003.
17. Kim TW, Kang YK, Ahn JH et al: Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 13: 1893-1898, 2002.
18. Shin D, Cho E, Lee WK et al: A phase II trial of epirubicin (E), cisplatin (C) and capecitabine (X) combination chemotherapy for previously untreated advanced gastric cancer (AGC). Proc ASCO 22: 328 (abstract), 2003.
19. Yeon Hee P, Choi SJ, Ryoo BY et al: A prospective phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer. Proc ASCO 22: 307 (abstract), 2003.
20. Sumpter KA, Harper-Whynne C, Cunningham D et al: Randomised, multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: confirmation dose escalation. Proc ASCO 22: 257 (Abstract), 2003.